Skip to content
mapperlab
← Dashboard
Stock

NEO

NEOGENOMICS, INC.
Health CareHealth Care ServicesLatest close $8.376 of 27 marquee funds currently hold2 CUSIPs mapped
Current holders
6
27 funds tracked
Ever held
8
Current + past
New this quarter
3
Exited this quarter
1

Marquee-fund ownership over time

May 12, 2023Nov 13, 2024Aug 14, 2025May 15, 2026
Now
7

This quarter's activity

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Bridgewater Associates re-entered$19$8.37-57%
Renaissance Technologies re-entered$17$8.37-49%
D.E. Shaw re-entered$0.00$8.37
Citadel Advisors$16$8.37-47%
Millennium Management re-entered$16$8.37-47%
AQR Capital Management$7.84$8.37+7%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Two Sigma Investments→ $8.24-28%
Point72 Asset Management→ $16-0%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at NEOGENOMICS INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
13
Filings · last 90d
15
Total on file
490
Recent SEC buffer
Most recent
Jun 3, 2026

30d / 90d windows measured from Jun 3, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 490 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · NEOGENOMICS, INC.

Annual figures sourced directly from NEOGENOMICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$727.33M
FY2025+10% YoY
Net income
-$108.03M
FY2025-37% YoY
EPS (diluted)
$-0.0400
FY2015
Free cash flow(?)
-$21.78M
FY2025+36% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for NEOGENOMICS INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Bridgewater AssociatesQ2 2026open$8.24$10+23%
Millennium ManagementQ2 2026open$0.00+0%
Renaissance TechnologiesQ2 2026open$8.36$8.37+0%
Two Sigma InvestmentsQ1 2026Q2 2026$11$8.24-28%
D.E. ShawQ3 2025open$6.20$8.37+35%
AQR Capital ManagementQ2 2025open$7.84$8.37+7%
Citadel AdvisorsQ4 2024open$16$8.37-47%
Millennium ManagementQ4 2024open$16$8.37-47%
D.E. ShawQ3 2024Q4 2024$0.00+0%
D.E. ShawQ3 2024Q2 2025$16$7.84-50%
Point72 Asset ManagementQ3 2024Q4 2024$16$16-0%
Renaissance TechnologiesQ3 2024Q4 2024$17$16-1%
Bridgewater AssociatesQ2 2023Q2 2025$19$7.96-59%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.